Results 101 to 110 of about 6,881 (206)

Deprescribing NSAIDs: The Potential Role of Community Pharmacists

Pharmacy
Non-steroidal anti-inflammatory drugs (NSAIDs) are largely used for controlling various pain conditions and are widely available in community pharmacies, with and without prescription. Despite their effectiveness, NSAIDs can pose significant risks due to
Delsher Amedi, Parisa Gazerani
doaj   +1 more source

Development and Validation of an XGBoost‐SHAP Model for Predicting Adverse Outcomes in Elderly Cardiovascular Patients With Polypharmacy: A Retrospective Cohort Study

Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT This study aims to develop and validate an interpretable machine learning model using Extreme Gradient Boosting (XGBoost) with SHapley Additive exPlanations (SHAP) analysis to predict adverse outcomes in elderly cardiovascular patients with polypharmacy. This retrospective cohort study included 1200 patients aged ≥ 65 years with cardiovascular
Kun Wang, Dandan Cao
wiley   +1 more source

Medication Burden: Beyond Counts to Recognize Polypharmacy as an Inherent Part of Living With Chronic Kidney Disease

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 2, August 2026.
ABSTRACT Medication burden in older patients with chronic kidney disease (CKD) is substantial, and simple medication counts are insufficient for identifying those at elevated risk of inappropriate prescribing. This study characterized medication burden by assessing the number of medications, potentially inappropriate medications (PIMs) and ...
Morten Baltzer Houlind, Helle Gybel Juul‐Larsen, Charlotte Strandhave, Niels Westergaard, Anne Estrup Olesen   +4 more
wiley   +1 more source

A Serverless Pharmacogenomic Risk Dashboard: Translating Ensemble Models and Model‐Based Scenario Rules to Clinical Decision Support

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT The “last mile” problem in healthcare AI—translating high‐performance models into accessible, privacy‐preserving point‐of‐care tools—remains unsolved for pharmacogenomic (PGx) risk assessment. No existing platform integrates opioid and polypharmacy risk scoring, model‐based scenario analysis, and CPIC‐based PGx patient cards within a single ...
R. Jerome Dixon, Elvin T. Price
wiley   +1 more source

Climate Change and Medications: Implications for Clinical Practice, Healthcare Sustainability, and Pharmacoepidemiology

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 8, August 2026.
Soko Setoguchi, Sean Hennessy
wiley   +1 more source

Deprescribing

Australian Prescriber, 2011
David Le Couteur, Emily Banks, Danijela Gnjidic, Andrew McLachlan   +3 more
openaire   +1 more source

Successful Benzodiazepine Deprescribing Assisted by Orengedokuto: A Case Series

Traditional &Kampo Medicine, Volume 13, Issue 2, August 2026.
Shinji Sato, Akito Hisanaga
wiley   +1 more source

Implementation of a deprescribing guideline by community pharmacists: A focus group study. [PDF]

Explor Res Clin Soc Pharm
Bakker S, Baas G, Bouvy ML, Denig P, Heringa M.   +4 more
europepmc   +1 more source

Refining MediQuit: an iterative, participatory approach to shared decision-making in deprescribing. [PDF]

Implement Sci Commun
Kornder N, Burkhardt S, Hierasimowicz K, Viniol A, Donner-Banzhoff N.   +4 more
europepmc   +1 more source

What Deprescribing Information Should Be Communicated on Discharge and How? A Qualitative Study of Pharmacists' Perspectives on Deprescribing at Transitions of Care. [PDF]

Australas J Ageing
Desforges K, Langford AV, McEvoy AM, Al Shieh MA, Turner JP, Dooley M, Roman CP, Reeve E.   +7 more
europepmc   +1 more source